Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Shanghai Junshi Biosciences Co., Ltd.
  6. Summary
    1877   CNE100003FF7

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.

(1877)
  Report
Delayed Hong Kong Stock Exchange  -  04:08 2022-08-19 am EDT
32.45 HKD   -1.67%
08/18Chinese Regulator Accepts Shanghai Junshi Biosciences's Drug, Supplemental Applications
MT
08/17Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection
GL
08/17Shanghai Junshi Biosciences Co., Ltd Receives the Acceptance Notice for the Investigational New Drug Application
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Hong Kong Stock Exchange
08/15/2022 08/16/2022 08/17/2022 08/18/2022 08/19/2022 Date
32.3(c) 31.7(c) 31.8(c) 33(c) 32.45 Last
937 200 1 012 600 652 200 2 399 800 1 660 400 Volume
+1.41% -1.86% +0.32% +3.77% -1.67% Change
More quotes
Estimated financial data (e)
Sales 2022 2 489 M 367 M 367 M
Net income 2022 -1 417 M -209 M -209 M
Net cash position 2022 2 110 M 311 M 311 M
P/E ratio 2022 -19,5x
Yield 2022 -
Sales 2023 4 639 M 684 M 684 M
Net income 2023 12,4 M 1,83 M 1,83 M
Net cash position 2023 5 268 M 776 M 776 M
P/E ratio 2023 -126x
Yield 2023 -
Capitalization 48 462 M 7 141 M 7 141 M
EV / Sales 2022 18,6x
EV / Sales 2023 9,31x
Nbr of Employees 2 805
Free-Float 21,3%
More Financials
Company
Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company develops innovative drugs and provides clinical research commercialization services worldwide. The Company mainly provides its products in the treatment of tumor immunotherapy, metabolic diseases, inflammation or autoimmune diseases, as well as nervous system diseases. The Company's... 
Read more
Sector
Pharmaceuticals
Calendar
08/31Earnings Release
More about the company
Ratings of Shanghai Junshi Biosciences Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
08/18Chinese Regulator Accepts Shanghai Junshi Biosciences's Drug, Supplemental Applications
MT
08/17Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indi..
GL
08/17Shanghai Junshi Biosciences Co., Ltd Receives the Acceptance Notice for the Investigati..
CI
08/17Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental Appl..
CI
07/25China approves Genuine Biotech's HIV drug for COVID patients
RE
07/22Shanghai Junshi Gets European Commission Designation for Nasopharyngeal Cancer Treatmen..
MT
07/21Shanghai Junshi Biosciences Co., Ltd. Announces Change of Address with Effect from Augu..
CI
07/21Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Comm..
GL
07/21Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Comm..
AQ
07/21Shanghai Junshi Biosciences Co., Ltd. Receives Orphan Medicinal Product Designation fro..
CI
07/13Chinese Regulator OKs Shanghai Junshi's Clinical Trial Application for Cancer Treatment
MT
07/12Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial Is..
CI
07/07Shanghai Junshi's Resubmission of Biologics License Application for Toripalimab Gets US..
MT
07/06Coherus BioSciences Says FDA Accepts Resubmission of Biologics License Application for ..
MT
07/06Junshi Biosciences and Coherus Announce FDA Acceptance of Resubmission of BLA for Torip..
GL
More news
News in other languages on SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
08/18L'organisme de réglementation chinois accepte les demandes de médicaments et de supplém..
08/17Shanghai Junshi Biosciences Co., Ltd reçoit l'avis d'acceptation de la demande de nouve..
08/17Shanghai Junshi Biosciences Co., Ltd. annonce l'acceptation de la demande supplémentair..
07/22Shanghai Junshi obtient la désignation de la Commission européenne pour son traitement ..
07/21Shanghai Junshi Biosciences Co., Ltd. reçoit la désignation de produit médicinal orphel..
More news
Analyst Recommendations on SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
More recommendations
Analysis
Drugmakers cut prices by 62% on average to get China state insurance listing
Chart SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Duration : Period :
Shanghai Junshi Biosciences Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 28,55 CNY
Average target price 56,94 CNY
Spread / Average Target 99,5%
EPS Revisions
Managers and Directors
Cong Li Co-Chief Executive Officer & Executive Director
Ning Li General Manager & Executive Director
Bao Hong Xu Financial Director
Jun Xiong Chairman
Yu Wu Chairman-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
SHANGHAI JUNSHI BIOSCIENCES CO., LTD.-43.10%7 141
CSL LIMITED2.92%100 157
SAMSUNG BIOLOGICS CO.,LTD.-3.10%46 957
WUXI BIOLOGICS (CAYMAN) INC.-22.53%38 992
BIOGEN INC.-9.83%31 394
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-25.52%21 880